The American Society of Hematology (ASH) has moved to a virtual platform for the 2020 Annual Meeting, and Janssen Oncology will have a strong showing at ASH with more than 35 company-sponsored presentations highlighting our deep, diverse oncology pipeline and portfolio.
Thank you for visiting the Janssen Oncology newsroom to learn more about our innovative approaches to advance science and deliver transformational medicines for patients
diagnosed with cancer.
You can learn more about what Janssen is doing to address the COVID-19 pandemic here.
Peter Lebowitz, M.D., Ph.D.
Global Therapeutic Area Head, Oncology
Janssen Research & Development, LLC.
President, Janssen Oncology
Janssen Pharmaceuticals, Inc.
Patient Advocate Perspectives
Myeloma Teacher Shares Hope for Multiple Myeloma Patients
CLL Patient Advocate Insight on Educating Yourself After Diagnosis